None listed
Conditions
Brief summary
Trial not undertaken due to COVID -19 pandemic forcing the withdrawal of this study before it commenced or approvals were gained.
Interventions
To create a database of physiological therapeutic responses to changes in FiO2 as captured by an inline data collecting box, for patients whilst on AIRVO2
MATERIALS
AIRVO2 flow source and Nasal High Flow cannula. An inline monitor will be installed in the circuit
PROCEDURES
All normal cares will prevail. One exception is the patient must wear a second independent SpO2 monitoring device on one of their fingers (Massimo SpO2 monitor a fully released and marketed device). The second device shall b
To create a database of physiological therapeutic responses to changes in FiO2 as captured by an inline data collecting box, for patients whilst on AIRVO2 MATERIALS AIRVO2 flow source and Nasal High Flow cannula. An inline monitor will be installed in the circuit PROCEDURES All normal cares will prevail. One exception is the patient must wear a second independent SpO2 monitoring device on one of their fingers (Massimo SpO2 monitor a fully released and marketed device). The second device shall be worn continuously whilst on ARIVO therapy for a maximum of 10 days average expected to be less then 48hrs (based on historical data)) WHO Consented Adult ICU patients with a requirement for respiratory support (delivered by AIRVO using nasal high flow cannula) as determined by the clinician in charge of their care. No other individual will be involved in the care of these patients DELIVERY All usual care shall prevail. The NHF shall be delivered by the ICU staff ( nurses and Drs) DURATION The therapy duration shall prevail as per standard care and by clinical need as determined by the clinician in charge of their care
Sponsors
Fisher & Paykel Healthcare
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged > 16 years 4. Ability to tolerate the therapy and be willing to adhere to the study intervention regimen 5. Agreement to adhere to therapy considerations throughout study duration
Exclusion criteria
An individual who meets any of the following criteria will be excluded from participation in this study: 1. Pregnancy or lactation 2. Known allergic reactions to, or contraindications to components of the study intervention 3. Involvement in another investigational study at the same time i.e. simultaneously
Outcome results
None listed